基于 Toll 样受体的免疫佐剂。
TLR-based immune adjuvants.
机构信息
Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, United States.
出版信息
Vaccine. 2011 Apr 12;29(17):3341-55. doi: 10.1016/j.vaccine.2010.08.002. Epub 2010 Aug 14.
Abstract
This work describes the nature and strength of the immune response induced by various Toll-like receptor ligands and their ability to act as vaccine adjuvants. It reviews the various ligands capable of triggering individual TLRs, and then focuses on the efficacy and safety of those agents for which clinical results are available.
摘要
本研究描述了各种 Toll 样受体配体诱导的免疫反应的性质和强度及其作为疫苗佐剂的能力。它回顾了能够触发个体 TLR 的各种配体，然后重点介绍了具有临床结果的那些药物的疗效和安全性。
相似文献
1
TLR-based immune adjuvants.
Vaccine. 2011 Apr 12;29(17):3341-55. doi: 10.1016/j.vaccine.2010.08.002. Epub 2010 Aug 14.
2
IABS international scientific workshop--Mode of Action of Adjuvants: implications for vaccine safety and design, April 29-30, 2010, Bethesda, MD, USA.
Vaccine. 2011 Apr 12;29(17):3340. doi: 10.1016/j.vaccine.2011.02.015. Epub 2011 Feb 16.
3
Adjuvants and delivery technologies.
Hum Vaccin. 2009 Oct;5(10):667-70. doi: 10.4161/hv.5.10.9140. Epub 2009 Oct 1.
4
Vaccine adjuvant safety: the elephant in the room.
Expert Rev Vaccines. 2013 Jul;12(7):715-7. doi: 10.1586/14760584.2013.811198.
5
Mucosal adjuvants.
Curr HIV Res. 2010 Jun;8(4):330-5. doi: 10.2174/157016210791208695.
6
Non-human primates as a model for understanding the mechanism of action of toll-like receptor-based vaccine adjuvants.
Curr Opin Immunol. 2017 Aug;47:1-7. doi: 10.1016/j.coi.2017.06.006. Epub 2017 Jul 15.
7
Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants.
Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12294-9. doi: 10.1073/pnas.1400478111. Epub 2014 Aug 18.
8
Drugs targeting Toll-like receptors.
Arch Pharm Res. 2009 Nov;32(11):1485-502. doi: 10.1007/s12272-009-2100-6.
9
TLR4 agonists as vaccine adjuvants: a chemist's perspective.
Expert Rev Vaccines. 2013 Jul;12(7):711-3. doi: 10.1586/14760584.2013.811189.
10
Novel vaccines and adjuvant systems: the utility of animal models for predicting immunogenicity in humans.
Hum Vaccin. 2008 May-Jun;4(3):246-50. doi: 10.4161/hv.4.3.5318. Epub 2010 May 18.
引用本文的文献
1
Leveraging innate immune signals in CD8+ T cells to boost antitumor immunity.
Front Immunol. 2025 Aug 29;16:1617773. doi: 10.3389/fimmu.2025.1617773. eCollection 2025.
2
Lipopeptide adjuvants for antibiotics and vaccines: the future step in the fight against multidrug-resistant and extensively drug-resistant pathogens.
Explor Drug Sci. 2024;2:203-233. doi: 10.37349/eds.2024.00043. Epub 2024 Apr 29.
3
Single-Cell Data and Weighted Correlation Network Analysis Revealed the Regulatory Mechanisms of Macrophages in Carotid Plaques.
J Immunol Res. 2025 Jul 21;2025:9987367. doi: 10.1155/jimr/9987367. eCollection 2025.
4
Engineered bacteria: Strategies and applications in cancer immunotherapy.
Fundam Res. 2024 Nov 13;5(3):1327-1345. doi: 10.1016/j.fmre.2024.11.001. eCollection 2025 May.
5
In Vivo Evaluation of PamCys-Modified Cancer-Testis Antigens as Potential Self-Adjuvanting Cancer Vaccines.
J Pept Sci. 2025 Jun;31(6):e70022. doi: 10.1002/psc.70022.
6
Ionizable lipid nanoparticles of mRNA vaccines elicit NF-κB and IRF responses through toll-like receptor 4.
NPJ Vaccines. 2025 Apr 17;10(1):73. doi: 10.1038/s41541-025-01124-x.
7
AI discovery of TLR agonist-driven phenotypes reveals unique features of peripheral cells from healthy donors and ART-suppressed people living with HIV.
Front Immunol. 2025 Mar 25;16:1541152. doi: 10.3389/fimmu.2025.1541152. eCollection 2025.
8
Multifaceted function of B cells in tumorigenesis.
Front Med. 2025 Apr;19(2):297-317. doi: 10.1007/s11684-025-1127-5. Epub 2025 Mar 22.
9
Optimizing rWTC-MBTA Vaccine Formulations, Dosing Regimens, and Cryopreservation Techniques to Enhance Anti-Metastatic Immunotherapy.
Int J Mol Sci. 2025 Feb 5;26(3):1340. doi: 10.3390/ijms26031340.
10
Calboxyvinyl polymer adjuvant enhances respiratory iga responses through mucosal and systemic administration.
NPJ Vaccines. 2025 Feb 11;10(1):28. doi: 10.1038/s41541-025-01086-0.
本文引用的文献
1
Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.
Vaccine. 2011 Aug 26;29(37):6313-20. doi: 10.1016/j.vaccine.2011.05.047. Epub 2011 May 30.
2
A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice.
Viral Immunol. 2010 Apr;23(2):201-10. doi: 10.1089/vim.2009.0107.
3
Toll-like receptor 8-mediated activation of murine plasmacytoid dendritic cells by vaccinia viral DNA.
Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6442-7. doi: 10.1073/pnas.0913291107. Epub 2010 Mar 22.
4
Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia.
Br J Cancer. 2010 Mar 30;102(7):1129-36. doi: 10.1038/sj.bjc.6605611. Epub 2010 Mar 16.
5
Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults.
PLoS One. 2010 Jan 22;5(1):e8787. doi: 10.1371/journal.pone.0008787.
6
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.
Clin Cancer Res. 2010 Jan 1;16(1):338-47. doi: 10.1158/1078-0432.CCR-09-2046.
7
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.
Lancet. 2009 Dec 12;374(9706):1975-85. doi: 10.1016/S0140-6736(09)61567-1.
8
Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis.
Vaccine. 2009 Dec 11;28(2):329-37. doi: 10.1016/j.vaccine.2009.10.045. Epub 2009 Oct 30.
9
A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults.
Vaccine. 2009 Dec 9;27(52):7292-8. doi: 10.1016/j.vaccine.2009.10.087. Epub 2009 Oct 27.
10
Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands.
Nat Immunol. 2009 Nov;10(11):1200-7. doi: 10.1038/ni.1792. Epub 2009 Oct 4.
Zotero 插件